Metsera, Inc. Common Stock (MTSR) - Total Assets
Based on the latest financial reports, Metsera, Inc. Common Stock (MTSR) holds total assets worth $639.66 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MTSR net asset value for net asset value and shareholders' equity analysis.
Metsera, Inc. Common Stock - Total Assets Trend (2022–2024)
This chart illustrates how Metsera, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Metsera, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Metsera, Inc. Common Stock's total assets of $639.66 Million consist of 79.6% current assets and 20.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $68.52 Million | 15.2% |
| Goodwill | $21.89 Million | 4.9% |
Asset Composition Trend (2022–2024)
This chart illustrates how Metsera, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Metsera, Inc. Common Stock (MTSR) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Metsera, Inc. Common Stock's current assets represent 79.6% of total assets in 2024, a decrease from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 78.2% of total assets in 2024, down from 100.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 0.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 15.2% of total assets.
Metsera, Inc. Common Stock Competitors by Total Assets
Key competitors of Metsera, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Metsera, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.26 | 3.81 | 3.81 |
| Quick Ratio | 5.26 | 3.81 | 3.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $435.77 Million | $56.63 Million | $56.63 Million |
Metsera, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Metsera, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.30 |
| Latest Market Cap to Assets Ratio | 9.14 |
| Asset Growth Rate (YoY) | 167.1% |
| Total Assets | $450.99 Million |
| Market Capitalization | $4.12 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Metsera, Inc. Common Stock's assets at a significant premium (9.14x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Metsera, Inc. Common Stock's assets grew by 167.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Metsera, Inc. Common Stock (2022–2024)
The table below shows the annual total assets of Metsera, Inc. Common Stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $450.99 Million | +167.11% |
| 2023-12-31 | $168.84 Million | +1027.11% |
| 2022-12-31 | $14.98 Million | -- |
About Metsera, Inc. Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to re… Read more